Inceptor Bio collaborating with U of Minnesota on new cancers therapies

Date Published:

Morrisville-headquartered biotechnology startup Inceptor Bio has inked a deal with the University of Minnesota to create a new cell-based tool to fight difficult-to-treat cancers.

The company said the partnership is to develop an iPSC – induced pluripotent stem cells – platform.

Inceptor plans to incorporate that technology into its own proprietary K62 CAR-M platform as a way to increase its capabilities. CAR-Macrophages (CAR-M) enter solid tumors and selectively destroy cancer cells, while also activating an adaptive immune response.

Inceptor plans to advance several cell therapy products into clinical studies using the combined iPSC/K62 platform. It said it would receive an exclusive license to any new technology developed as part of the collaboration.

“iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies,” said Mike Nicholson, Ph.D., president and chief operating officer of Inceptor. “We are excited to work with Dr. Beau Webber at the University of Minnesota and his team to develop this unique platform.”

Abe Maingi, Inceptor’s vice president of business development, added that the partnership “is an important step in continuing to execute on our strategy of advancing cell therapies to bring a more positive prognosis and quality of life to patients with difficult-to-treat cancers.”

Inceptor was established in 2020. The company focuses on ways to strengthen immune cell performance in parts of the body where cancer is found, with the goal of moving those treatments from the laboratory to clinical development as rapidly as possible.

Inceptor is developing multiple cell therapy platforms across cell types that include CAR-M, CAR-T (cells engineered to identify and kill cancer cells) and CAR-NK (CAR-Natural Killer cells engineered to identify and attack cancer).

© NC Biotech Center

Original Article Source: WRAL Techwire